Capsida Biotherapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.capsida.com
A Clinical Trial of CAP-002 Gene Therapy in Pediatric Patients With Syntaxin-Binding Protein 1 (STXBP1) Encephalopathy
Phase 1
Not yet recruiting
- Conditions
- Developmental and Epileptic Encephalopathy
- Interventions
- Drug: gene therapy
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Capsida Biotherapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT06983158
- Locations
- 🇺🇸
Colorado Child Health Research Institute, Aurora, Colorado, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Robert's Centre for Pediatric Research, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Natural History Study in Pediatric Patients with STXBP1 Encephalopathy with Epilepsy
Withdrawn
- Conditions
- STXBP1 Encephalopathy with Epilepsy
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Capsida Biotherapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05462054
© Copyright 2025. All Rights Reserved by MedPath